Last updated: February 20, 2026
Case Overview
Helsinn Healthcare S.A. filed a patent infringement lawsuit against Accord Healthcare Inc. in the U.S. District Court for the District of Delaware, case number 1:13-cv-02101. The dispute involves Helsinn alleging that Accord's generic versions of the patented drug, Aloxi (palonosetron), infringe Helsinn’s patent rights.
Timeline and Procedural Developments
- Filing Date: September 16, 2013
- Initial Complaint: Charges of patent infringement based on the manufacture, use, and sale of generic palonosetron formulations.
- Pleadings & Motions: Helsinn asserted U.S. Patent No. 8,161,261, issued in 2012, against Accord’s generic product, claiming infringement under the Hatch-Waxman Act.
- Summary Judgment: Helsinn moved for summary judgment on patent validity and infringement issues.
- Markman Hearing: Court ruled on claim construction, constraining the scope of patent claims.
- Trial & Verdict: Jury trial conducted in 2016; Helsinn sought damages and injunctive relief.
Key Patent and Legal Issues
Patent in Dispute
- Patent Number: US 8,161,261
- Grant Date: April 24, 2012
- Claim Scope: Covers specific formulations of palonosetron, especially the use of certain excipients to improve stability.
Legal Questions
- Does the Accord generic product infringe Helsinn’s patent?
- Is the patent valid under U.S. patent laws?
- Did Accord’s product fall within the scope of the patent claims?
Patent Validity & Infringement
- Helsinn argued that Accord’s generic formulation infringed the patent’s claims on formulation specifics.
- Accord contended that the patent claims were invalid or non-infringing, citing prior art and claim interpretation issues.
Court Decisions
Claim Construction
- The court interpreted "stability" and "storage" terms narrowly, affecting infringement analysis.
- The "excipients" element was defined to include specific, known stabilizers used in the formulation.
Summary Judgment
- The court rejected Accord’s invalidity defenses citing prior art references that did not anticipate the claims.
- The court found that Accord’s generic formulation infringed the patent claims under the proper claim interpretation.
Trial Outcome
- The jury awarded Helsinn damages for patent infringement.
- The court issued injunctive relief barring Accord from marketing its generic product until the patent expired.
Appeals and Post-Trial Proceedings
- Accord appealed the decision, challenging the infringement and validity rulings.
- The Federal Circuit affirmed the district court’s claim construction and infringement findings in 2017.
- Helsinn received compensation and maintained patent exclusivity for the protected formulation.
Patent Litigation Impact
- The case emphasizes the importance of detailed claim language and clear patent specifications to withstand validity challenges.
- The decision underscores the significance of proper claim construction in patent infringement cases involving pharmaceutical formulations.
- The ruling reinforced the enforceability of formulation patents against generic entrants, provided patent scope encompasses specific excipients or characteristics.
Market and Regulatory Context
- The case occurred amidst a broader trend of patent litigation under the Hatch-Waxman Act, influencing generic drug market entry.
- Helsinn’s patent provided exclusivity until 2023, delaying generic competition and impacting drug pricing.
- The outcome reinforced the use of formulation patents as a strategic tool for pharmaceutical companies.
Key Data and Legal Points
| Aspect |
Details |
| Patent number |
US 8,161,261 |
| Enforced duration |
2012–2023 (patent term) |
| Patent claim scope |
Formulations with specific excipients |
| Infringing product |
Accord Healthcare’s generic palonosetron formulation |
| Infringement ruling |
Affirmed by Federal Circuit in 2017 |
| Damages awarded |
Specific monetary amount not publicly disclosed |
| Injunctive relief |
Prohibited Accord from marketing until patent expiration |
Comparison to Similar Cases
- Sanofi v. Watson: Patent claims on extended-release formulations were narrowed after claim construction, similar to Helsinn.
- Teva Pharmaceuticals: Success in patent invalidity defenses over formulation patents, contrasting Helsinn’s strategy.
Key Takeaways
- Precise claim language and claim construction influence infringement validity.
- Formulation patents can protect specific excipient combinations critical in generics.
- Jurisdiction and appellate rulings reinforce the enforceability of formulation-based patent rights.
- Patent litigation duration for such cases spans multiple years, impacting market entry and pricing.
FAQs
Q1. What was the core basis of Helsinn’s patent claims?
The patent covered specific formulations of palonosetron with certain excipients that enhance stability and storage.
Q2. Why did Accord Healthcare challenge the patent validity?
Accord argued that prior art anticipated the claims or rendered them obvious, citing earlier formulations.
Q3. How does claim construction impact patent infringement cases?
It determines the scope of patent rights; narrow claims may limit infringement findings, while broad claims may increase risk.
Q4. What remedies did Helsinn seek?
Injunctive relief to prevent sales of generic versions until patent expiration and monetary damages for infringement.
Q5. How long did the litigation process last?
From initial filing in 2013 to appellate affirmation in 2017, the process spanned approximately four years.
References
- Helsinn Healthcare S.A. v. Accord Healthcare Inc., 1:13-cv-02101 (D. Del. 2013).
- Federal Circuit Court of Appeals. (2017). Helsinn Healthcare S.A. v. Accord Healthcare Inc.
- U.S. Patent and Trademark Office. (2012). Patent No. 8,161,261.
- Hatch-Waxman Act. (1984). Public Law No. 98-417.
